Allurion shares surge 13.89% intraday after announcing 23% weight loss and 14% lean mass gain in tirzepatide combination study.

Allurion Technologies Inc. surged 13.89% intraday following the announcement of positive clinical results combining its Smart Capsule with low-dose tirzepatide. The study showed an average 23% total weight loss and a 14% increase in lean body mass over 12 months, with all patients adhering to the regimen—addressing key limitations of GLP-1 therapies such as muscle loss and poor adherence. The company highlighted the combination’s potential to become a new standard of care, leveraging its AI-powered virtual care suite for monitoring. These results, presented in a case series of 76 patients, contrasted with prior GLP-1 trials where 58% of patients discontinued therapy. The data, expected to be shared at upcoming medical meetings, underscored Allurion’s strategic shift toward combination therapies and reinforced optimism about its metabolically healthy weight-loss platform.